Literature DB >> 12570121

Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998-2000.

G B Migliori1, R Centis, L Fattorini, G Besozzi, C Saltini, G Orefici, C Piersimoni, A Gori, A Cassone.   

Abstract

In 1998 a network of 20 regional tuberculosis (TB) laboratories (the Italian Multicentre Study on Resistance to Antituberculosis drugs (SMIRA) network) was established in Italy to implement proficiency testing and to monitor the prevalence of drug resistance nationwide. The network managed 30% of all TB cases reported in Italy each year. The aim of the present report is to describe: 1) the accuracy of drug-susceptibility testing in the network; 2) the prevalence of drug resistance for the period 1998-2000. Data were collected from the network laboratories. Sensitivity to streptomycin and ethambutol increased from the first survey (1998-1999) to the second survey (2000) from 87.7 to 91.9%. Specificity, predictive values for resistance and susceptibility, efficiency and reproducibility were consistent in both surveys. In previously untreated cases, the prevalence of multidrug-resistance was the same in both surveys (1.2%), while a slight decrease from the first to the second survey was observed for monoresistance to rifampicin (from 0.8 to 0.4%) and isoniazid (from 2.9 to 2%). The significant association found between isoniazid resistance and immigration is a useful indicator for both clinicians managing individual tuberculosis cases and public health services planning control strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12570121     DOI: 10.1183/09031936.03.00047402

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  3 in total

1.  Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy.

Authors:  Paolo Miotto; Federica Piana; Valeria Penati; Filippo Canducci; Giovanni Battista Migliori; Daniela Maria Cirillo
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

Review 2.  Risk factors for multidrug resistant tuberculosis in Europe: a systematic review.

Authors:  A Faustini; A J Hall; C A Perucci
Journal:  Thorax       Date:  2005-10-27       Impact factor: 9.139

Review 3.  Mycobacterium lentiflavum infection in immunocompetent patient.

Authors:  Chiara Molteni; Lidia Gazzola; Miriam Cesari; Alessandra Lombardi; Franco Salerno; Enrico Tortoli; Luigi Codecasa; Valeria Penati; Fabio Franzetti; Andrea Gori
Journal:  Emerg Infect Dis       Date:  2005-01       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.